Regeneron es una acción biotecnológica de primer nivel impulsada por su plataforma de descubrimiento de anticuerpos líder en la industria y el crecimiento explosivo de Dupixent en múltiples indicaciones inflamatorias, demostrando el tipo de innovación impulsada por la ciencia y ejecución comercial que buscan los inversores de biotecnología.
Data updated Feb 15 · Source: Twelve Data
Regeneron Pharmaceuticals stands as one of biotech's most successful commercial-stage companies, anchored by blockbuster Eylea (ophthalmology) and Dupixent (immunology), the latter co-marketed with Sanofi and still in a robust growth trajectory across multiple indications. The company's strong R&D engine consistently delivers pipeline candidates, with promising programs in oncology (Libtayo), obesity, and next-generation antibody platforms.
Financially, REGN is impressive: EPS of $24.51 TTM reflects genuine profitability uncommon in biotech. The stock has surged 37% over 90 days, now trading near its 52-week high of $821, suggesting strong momentum but limited near-term upside margin. The P/E of 32.77 is elevated relative to historical norms but reasonable given Dupixent's growth runway.
Bull case: Dupixent label expansions, robust pipeline including obesity candidates, and consistent execution. Bear case: Eylea biosimilar competition is intensifying, the valuation leaves little room for disappointment, and pipeline setbacks could pressure the stock significantly. Regeneron remains a core biotech holding for growth-oriented investors willing to accept premium pricing for quality.
Regeneron Pharmaceuticals remains a powerhouse in the biotech sector, anchored by its blockbuster immunology drug Dupixent and its ophthalmology franchise. With a P/E ratio of 30.8, the stock commands a premium, largely justified by Dupixent's continued double-digit growth and expansion into new indications like COPD. The launch of Eylea HD is a strategic pivot designed to defend market share against Roche's Vabysmo in the competitive eye-disease landscape. Financially, the company is robust with strong free cash flow and a solid EPS of $24.51. However, investors must weigh the bullish pipeline against risks regarding the patent cliff for standard Eylea and broader drug pricing pressures. While the stock is trading near its 50-day moving average, Regeneron stands out as a blue-chip holding in a volatile sector, offering stability and growth potential for long-term portfolios.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Cada trader tiene una estrategia que se ve genial en su cabeza. El backtesting es cómo descubres si realmente funciona. Aquí hay cómo probar estrategias correctamente, qué métricas importan y por qué la mayoría de los resultados de backtest son demasiado buenos para ser verdad.
Powered by Rexiew